Molecular Screening Test Detects Colorectal Cancer
|
By LabMedica International staff writers Posted on 12 Oct 2010 |

Image: Colored scanning electron micrograph (SEM) of cancer cells from the human colon (photo courtesy Susumu Nishinaga / SPL).
A ribonucleic acid (RNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity.
Blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer and sex- and age-matched healthy volunteers were screened using a state of the art method for micro RNA (miRNA).
The method was based on the miRCURY locked nucleic acid (LNA) Universal reverse transcriptase miRNA polymerase chain reaction analysis. Early-stage colorectal cancer could be distinguished from healthy subjects with good sensitivity and specificity from a single plasma sample of less than 1 mL of blood.
The miRCURY LIN assays are manufactured by Exiqon A/S, (Vedbaek, Denmark). Exiqon's miRNA arrays feature normalized enhanced LNA capture probes, designed for excellent specificity and sensitivity even for AT-rich miRNAs. In addition, they offer great reproducibility with 99% correlation between arrays and a dynamic range greater than four orders of magnitude.
Colorectal cancer is the second leading cause of cancer-related deaths in the western world. If diagnosed early, the disease can usually be cured with surgery; however, the prognosis for late-stage cancer is bleak. Although several early-detection screening methods are available, current estimates suggest that less than half of Americans over the age of 50 receive adequate colorectal cancer screening. The findings were presented at the Fourth American Association for Cancer Research's International Conference on Molecular Diagnostics in Cancer Therapeutic Development that was held during September 23 – 27, 2010, in Denver (CO, USA).
Søren Jensby Nielsen, Ph.D., scientific manager, Exiqon A/S, said, "Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup."
Nielsen and colleagues are starting a large, prospective clinical trial in symptomatic individuals undergoing colonoscopy to validate prospectively their screening test. The scientist envision that this type of miRNA profile, once developed and marketed as a screening kit, can be used to screen entire populations in order to facilitate a focused selection of individuals who should undergo colonoscopy.
Related Links:
Exiqon A/S
Blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer and sex- and age-matched healthy volunteers were screened using a state of the art method for micro RNA (miRNA).
The method was based on the miRCURY locked nucleic acid (LNA) Universal reverse transcriptase miRNA polymerase chain reaction analysis. Early-stage colorectal cancer could be distinguished from healthy subjects with good sensitivity and specificity from a single plasma sample of less than 1 mL of blood.
The miRCURY LIN assays are manufactured by Exiqon A/S, (Vedbaek, Denmark). Exiqon's miRNA arrays feature normalized enhanced LNA capture probes, designed for excellent specificity and sensitivity even for AT-rich miRNAs. In addition, they offer great reproducibility with 99% correlation between arrays and a dynamic range greater than four orders of magnitude.
Colorectal cancer is the second leading cause of cancer-related deaths in the western world. If diagnosed early, the disease can usually be cured with surgery; however, the prognosis for late-stage cancer is bleak. Although several early-detection screening methods are available, current estimates suggest that less than half of Americans over the age of 50 receive adequate colorectal cancer screening. The findings were presented at the Fourth American Association for Cancer Research's International Conference on Molecular Diagnostics in Cancer Therapeutic Development that was held during September 23 – 27, 2010, in Denver (CO, USA).
Søren Jensby Nielsen, Ph.D., scientific manager, Exiqon A/S, said, "Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup."
Nielsen and colleagues are starting a large, prospective clinical trial in symptomatic individuals undergoing colonoscopy to validate prospectively their screening test. The scientist envision that this type of miRNA profile, once developed and marketed as a screening kit, can be used to screen entire populations in order to facilitate a focused selection of individuals who should undergo colonoscopy.
Related Links:
Exiqon A/S
Latest Molecular Diagnostics News
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
- Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
- AI Tool Automates Variant Curation and Interpretation for Cancer Whole-Genome Sequencing
- Portable Test Detects Zika and Hepatitis C RNA from Whole Blood
- DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
- Blood-Based Test May Predict Response Across Rheumatoid Arthritis Drug Classes
- New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma
Channels
Clinical Chemistry
view channel
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more
Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







.jpg)